PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

| TRANSMITTAL | Application Number | ollection of information unless it displays a valid OMB control number. 10/668,057 |
|---|------------------------|--|
| TRANSMITTAL | Filing Date | September 22, 2003 |
| FORM | First Named Inventor | Anthony D. Sandler |
| | Art Unit | 1634 |
| (to be used for all correspondence after initial fi | Examiner Name | Bradley L. Sisson |
| Total Number of Pages in This Submission 21 | Attorney Docket Number | 17023.032US1 |
| | | |

| ENCLOSURES (Check all that apply) | | | | | |
|--|--|---|----------------|--|------------------------------|
| Amendmer Afte Affi Extension of Express Ab | e Attached | Petition Petition Petition Power of Attorney, Revocat Change of Correspondence Terminal Disclaimer Request for Refund CD, Number of CD(s) | ion Address | After Appear of Appear (Appear (Appear) Status Other below Form 1449 (| 1 pg.) ree (3) references |
| Certified Condition Certified Condition Document(Reply to Mincomplete Reply to Mincomplete und | opy of Priority s) issing Parts/ Application ply to Missing Parts der 37 CFR 1.52 or 1.53 | Landscape Table on C | CD | OR AGENT | |
| Firm Name VIKSNINS HARRIS & PADYS PLLP | | | | | |
| Signature | | | | | |
| Printed name Peter L. Malen | | | | | |
| Date | ate March 20, 2006 Reg. No. 44,894 | | | | |
| CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: | | | | | |
| Signature | 1 1 /) | Mau | | | |
| Typed or printed na | , , , , , , , , , , , , , , , , , , , | - , , , , , , , , , , , , , , , , , , , | | Date | March 20, 2006 |

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Anthony D. Sandler

Examiner:

Bradley L. Sisson

Serial No.:

10/668.057

Group Art Unit:

1634

Filed:

September 22, 2003

Docket:

17023.032US1

Title:

METHOD FOR PREDICTING TUMOR RECURRENCE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicant requests that a copy of the Form 1449, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Pursuant to 37 C.F.R. § 1.97, no fee or statement is required with the Information Disclosure Statement. However, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 503503 in order to have this Information Disclosure Statement considered. The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

> Respectfully submitted, Anthony D. Sandler By his Representatives, Viksnins Harris & Padys PLLP P.O. Box 111098 - St. Paul, MN 55111 952 876-4094

Date March 20,200 6

Peter L Malen

Reg. No. 44,894

CERTIFICATE UNDER 37 CFR 1.8: I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment; Commissioner for Patents; P.O. Box 1450, Alexandria, VA 22313-1450, on this 2006.

Substitute for form 1449A/PTO and/or 1449B/PTO

| INFORMATION DISCLOSURE | Complete if Known | | |
|---|----------------------|-----|--|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT Use as many sheets as necessary) | Application Number | | |
| | Filing Date | Sep | |
| | First Named Inventor | San | |
| | Group Art Unit | 163 | |
| | Examiner Name | Bra | |
| G/ | | | |

| 10/660 057 | | |
|---------------------------------|--|--|
| 10/668,057 | | |
| September 22, 2003 | | |
| First Named Inventor Sandler | | |
| Group Art Unit 1634 | | |
| Examiner Name Bradley L. Sisson | | |
| 7023.032US1 | | |
| | | |

| US PATENT DOCUMENTS | | | |
|---------------------|---------------------------|------------|--|
| Examiner Initials * | Traine of a defined to be | | Name of Patentee/Applicant of Document |
| | 6,656,684 | 12/02/2003 | Sandler |

| FOREIGN PATENT DOCUMENTS | | | |
|--------------------------|--|---|--|
| Examiner Initials* | Foreign Document Number (include country code) | Publication Date Translation (Abstract Only Translation, if applicable) | |
| | | | |

| | OTHER DOCUMENTS NON PATENT LITERATURE DOCUMENTS | | |
|--------------------|--|--|--|
| Examiner Initials* | (| | |
| | Azuhata et al., "The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma", <u>J Pediatr Surg.</u> , <u>36(12)</u> , 1785-1791 (2001). | | |
| - 55 | Sandler et al., "The survivin:fas ratio is predictive of recurrent disease in neuroblastoma", <u>J</u> Pediatr Surg., <u>37(3)</u> , 507-511 (2002). | | |
| | Takamizawa et al., "The survivin:fas ratio in pediatric renal tumors", <u>J Pediatr Surg.</u> , <u>36(1)</u> , 37-42 (2001). | | |